PUBLISHER: IMARC | PRODUCT CODE: 1468260
PUBLISHER: IMARC | PRODUCT CODE: 1468260
Ischemic Heart Disease Drugs Market Report by Disease Class, Drug Class, and Region 2024-2032
The global ischemic heart disease (IHD) drugs market size reached US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.9% during 2024-2032.
Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.
The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on disease class and drug class.
Breakup by Disease Class:
Angina Pectoris
Myocardial Infarction
Breakup by Drug Class:
Anti-Dyslipidemic Drugs
Calcium Channel Blockers
Beta-Blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents
Breakup by Region:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.
Key Questions Answered in This Report:
- How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
- What is the breakup of the market based on the disease class?
- What is the breakup of the market based on the drug class?
- What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
- What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
- What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
- What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
- What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Ischemic Heart Disease (IHD) Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Disease Class
- 6.1 Angina Pectoris
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Myocardial Infarction
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Drug Class
- 7.1 Anti-Dyslipidemic Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Calcium Channel Blockers
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Beta-Blockers
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 ACE Inhibitors
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 ARBs
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Vasodilators
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Antithrombotic Agents
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Europe
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Asia Pacific
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Middle East and Africa
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Latin America
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Bayer AG
- 13.3.2 Eli Lilly and Company
- 13.3.3 Novartis International AG
- 13.3.4 Pfizer, Inc.
- 13.3.5 Sanofi S.A.
- 13.3.6 Actelion Pharmaceuticals Ltd.
- 13.3.7 Baxter International Inc.
- 13.3.8 Boehringer Ingelheim International GmbH
- 13.3.9 Bristol-Myers Squibb Company
- 13.3.10 Amgen Inc.
- 13.3.11 F. Hoffmann-La Roche AG
- 13.3.12 GlaxoSmithKline Plc
- 13.3.13 Merck & Co.
- 13.3.14 Eisai Co., Ltd.
List of Figures
- Figure 1: Global: Ischemic Heart Disease Drugs Market: Major Drivers and Challenges
- Figure 2: Global: Ischemic Heart Disease Drugs Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Ischemic Heart Disease Drugs Market: Breakup by Disease Class (in %), 2023
- Figure 4: Global: Ischemic Heart Disease Drugs Market: Breakup by Drug Class (in %), 2023
- Figure 5: Global: Ischemic Heart Disease Drugs Market: Breakup by Region (in %), 2023
- Figure 6: Global: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 7: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 8: Global: Ischemic Heart Disease Drugs (Angina Pectoris) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 9: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 10: Global: Ischemic Heart Disease Drugs (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 11: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 12: Global: Ischemic Heart Disease Drugs (Anti-Dyslipidemic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 13: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 14: Global: Ischemic Heart Disease Drugs (Calcium Channel Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 15: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 16: Global: Ischemic Heart Disease Drugs (Beta-Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 17: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 18: Global: Ischemic Heart Disease Drugs (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 19: Global: Ischemic Heart Disease Drugs (ARBs) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 20: Global: Ischemic Heart Disease Drugs (ARBs) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 21: Global: Ischemic Heart Disease Drugs (Vasodilators) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 22: Global: Ischemic Heart Disease Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 23: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 24: Global: Ischemic Heart Disease Drugs (Antithrombotic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 25: North America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 26: North America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 27: Europe: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 28: Europe: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 29: Asia Pacific: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 30: Asia Pacific: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 31: Middle East and Africa: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 32: Middle East and Africa: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 33: Latin America: Ischemic Heart Disease Drugs Market: Sales Value (in Million US$), 2018 & 2023
- Figure 34: Latin America: Ischemic Heart Disease Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 35: Global: Ischemic Heart Disease Drugs Industry: SWOT Analysis
- Figure 36: Global: Ischemic Heart Disease Drugs Industry: Value Chain Analysis
- Figure 37: Global: Ischemic Heart Disease Drugs Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Ischemic Heart Disease Drugs Market: Key Industry Highlights, 2023 and 2032
- Table 2: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Disease Class (in Million US$), 2024-2032
- Table 3: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
- Table 4: Global: Ischemic Heart Disease Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 5: Global: Ischemic Heart Disease Drugs Market: Competitive Structure
- Table 6: Global: Ischemic Heart Disease Drugs Market: Key Players
